Can commercial serum neural-autoantibody panels produce false-positive or clinically irrelevant results?

Commercial neural-autoantibody panels can be valuable when ordered for a compatible neurologic syndrome, but a serum result alone—especially an unexpected broad pattern—does not establish autoimmune neurologic disease.

Clinical validity and interpretation

• In a 2016–2022 reference-laboratory cohort, 39/63 interpretable serum-positive results (61.9%) were considered nonspecific; 35 of those patients had an alternative diagnosis.
• Serum testing had substantially lower positive predictive value than CSF testing (44.0% vs 88.8%). Clinically irrelevant serum-only reactivity was reported for low-level GAD65, NMDAR, Yo, GABA-B-R, and CV2 antibodies.
• Multiple reported antibodies should not be treated as cumulative proof of autoimmunity. Each must independently match a recognized phenotype, relevant ancillary findings, specimen source, and assay performance. In unselected testing populations, positive predictive value has been reported as only 3.57%.

Assay and biologic considerations

• Unconfirmed commercial line-blot reactivity is particularly unreliable: in one cohort, only 8% of line-blot-positive/tissue-test-negative results were true positives, versus 91% when tissue-based testing was concordant.
• Low-titer, serum-only, phenotype-discordant, and intracellular-antigen line-blot results are therefore most susceptible to nonspecific reactivity. Diagnostic interpretation centers on IgG antibodies; isolated IgM or IgA neuronal-antibody findings are not decisive.
• Paired serum and CSF testing can resolve discordance. CSF is particularly important for many neuronal-surface antibodies, whereas serum can be more sensitive for selected targets such as LGI1.

Clinical implications

• Confirmation in an experienced/reference laboratory using an orthogonal method—often tissue-based screening plus antigen-specific cell-based or protein-based assays—should precede diagnostic attribution, particularly for atypical or weak serum findings.
• Bottom line: The claim is supported. Commercial serum panels can generate false-positive or clinically irrelevant findings, and multi-antibody patterns without a coherent neurologic syndrome warrant heightened caution, independent confirmation, and interpretation within the full clinical and alternative-diagnosis context.